Fibrogen Inc (FGEN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Fibrogen reported revenue of $6.4M, down 78.3% from $29.6M the year before. Net income was $183.5M (a 2848.6% net margin), or $45.37 per diluted share. Gross margin was 91.4% and operating margin was -712.7%. Operating activities generated -$4.8M of cash, leaving -$4.8M of free cash flow. At fiscal year end, Fibrogen held $119.6M in total assets against $115.1M in total liabilities, including $47.9M of cash and equivalents.
Open the full interactive Fibrogen financials → Quarterly statements, key ratios, valuation history and price charts.
Fibrogen Key Stats
| Share Price | $5.87 |
|---|---|
| Market Cap | $23.8M |
| P/E Ratio | 0.1 |
| Revenue YoY Growth | -78.3% |
| 52-Week Range | $5.87 – $11.18 |
| Shares Outstanding | 4.0 million (basic, 2026 Q2) |
Fibrogen Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $176.3M | $235.3M | $140.7M | $147.8M | $29.6M | $6.4M |
| Cost of Goods Sold | — | $523.8M | $441.8M | $429.6M | $180.0M | $52.3M |
| Gross Profit | — | $222.4M | $120.5M | $128.9M | $14.1M | $5.9M |
| Operating Income | -$191.9M | -$288.5M | -$301.0M | -$281.8M | -$150.4M | -$45.9M |
| Pre-Tax Income | -$188.9M | -$290.7M | -$294.9M | -$286.9M | -$153.4M | -$58.3M |
| Income Tax | $360,000 | $347,000 | $358,000 | $3,000 | -$269,000 | -$90,000 |
| Net Income | -$189.3M | -$290.0M | -$293.7M | -$284.2M | -$47.6M | $183.5M |
| Diluted EPS | -$52.75 | -$78.50 | -$78.50 | -$73.00 | -$12.00 | $45.37 |
Fibrogen Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.1M | $1.3M | $3.7M | -$1.5M |
| Net Income | $200.6M | -$14.2M | -$15.2M | $12.0M |
| Diluted EPS | $49.61 | -$3.52 | -$3.76 | $2.96 |
Fibrogen Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $678.4M | $171.2M | $155.7M | $113.7M | $50.5M | $47.9M |
| Current Assets | $755.1M | $474.1M | $492.8M | $331.6M | $196.5M | $99.1M |
| Total Assets | $826.8M | $773.8M | $610.1M | $423.5M | $214.5M | $119.6M |
| Current Liabilities | $163.2M | $225.5M | $273.6M | $217.7M | $133.3M | $29.2M |
| Total Long-Term Debt | — | — | — | $71.9M | $73.1M | — |
| Total Liabilities | $385.4M | $544.7M | $611.6M | $585.7M | $398.2M | $115.1M |
| Shareholders' Equity | $422.2M | $209.1M | -$21.4M | -$204.2M | -$225.6M | -$30.0M |
Fibrogen Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $81.6M | -$82.2M | -$145.9M | -$315.0M | -$138.0M | -$4.8M |
| Cash From Investing | $452.5M | -$427.0M | $89.1M | $153.7M | $126.0M | $35.4M |
| Cash From Financing | $13.3M | -$563,000 | $46.8M | $122.7M | -$255,000 | -$86.0M |
| Free Cash Flow | $77.6M | -$87.4M | -$149.7M | -$317.5M | -$138.3M | -$4.8M |
Figures from Fibrogen's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Fibrogen financials page for every line item.
Fibrogen Company Profile
| Ticker | FGEN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Francisco, California |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000921299 |
Frequently Asked Questions
What was Fibrogen's revenue in fiscal 2025?
Fibrogen (FGEN) reported revenue of $6.4M for fiscal 2025.
What is Fibrogen's annual revenue history?
Fibrogen's annual revenue by fiscal year: 2020: $176.3M; 2021: $235.3M; 2022: $140.7M; 2023: $147.8M; 2024: $29.6M; 2025: $6.4M.
What was Fibrogen's net income in fiscal 2025?
Fibrogen reported net income of $183.5M for fiscal 2025.
What was Fibrogen's earnings per share (EPS) in fiscal 2025?
Fibrogen's diluted EPS was $45.37 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Fibrogen generate in fiscal 2025?
Fibrogen generated -$4.8M of free cash flow in fiscal 2025.
What was Fibrogen's revenue last quarter?
In its most recent reported quarter (2026 Q2), Fibrogen reported revenue of -$1.5M.
How many shares of Fibrogen are outstanding?
Fibrogen reported a weighted average of 4.0 million basic shares outstanding in 2026 Q2.
What is Fibrogen's market cap?
Based on its latest closing price, Fibrogen (FGEN) has a market capitalization of about $23.8M.
When does Fibrogen's fiscal year end?
Fibrogen's fiscal year end, as registered with the SEC, is December 31.
Where is Fibrogen headquartered?
Fibrogen lists its business address in San Francisco, California in its SEC filings.